Holen Sie sich die Stockscreener-App
0.1584
1.01%
0.0003
Schlusskurs vom Vortag:
$0.1581
Offen:
$0.1543
24-Stunden-Volumen:
151.97K
Relative Volume:
0.07
Marktkapitalisierung:
$12.99M
Einnahmen:
$11.00M
Nettoeinkommen (Verlust:
$-64.71M
KGV:
-0.1378
EPS:
-1.1496
Netto-Cashflow:
$-57.52M
1W Leistung:
+2.18%
1M Leistung:
-32.73%
6M Leistung:
-76.13%
1J Leistung:
-57.37%
1-Tages-Spanne:
$0.1536
$0.1599
1-Wochen-Bereich:
$0.148
$0.178
52-Wochen-Spanne:
$0.13
$1.43
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.1568 | 13.10M | 11.00M | -64.71M | -57.52M | -1.1496 |
VRTX
Vertex Pharmaceuticals Inc
|
454.58 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
757.29 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.58 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
690.88 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.96 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-08-13 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
Buyout Rumor: Can BioAtla Inc deliver consistent dividends2026 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
BioAtla, Inc. 8-K SEC Filing March 17, 2026: Company Information, Key Details, and Legal Disclosures - Minichart
BioAtla Shareholders Approve Merger and Share Consolidation - TipRanks
BioAtla (NASDAQ: BCAB) approves merger, 1-for-50 reverse split and 2026 executive retention bonuses - Stock Titan
842,440 shares issued to YA II PN, Ltd.; BioAtla (NASDAQ: BCAB) registers resale - Stock Titan
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
Breakout Watch: What is the dividend yield of BioAtla IncEarnings Growth Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BioAtla (NASDAQ: BCAB) to issue 631,163 shares to Yorkville under SEPA - Stock Titan
BioAtla (NASDAQ: BCAB) CMO receives 240,000-share time-based RSU award - Stock Titan
BioAtla (NASDAQ: BCAB) CEO receives 430,000-share RSU grant - Stock Titan
BioAtla (BCAB) CFO awarded 240,000 restricted stock units, total holdings 530,196 shares - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Published on: 2026-03-07 14:29:43 - Naître et grandir
BioAtla launches major restructuring and leadership transition - The Globe and Mail
BioAtla explores sale as it cuts 70% of workforce - Investing.com South Africa
BioAtla (BCAB) CFO sees 1,802 shares withheld for RSU tax settlement - Stock Titan
[Form 4] BioAtla, Inc. Insider Trading Activity - Stock Titan
BioAtla (BCAB) CMO reports 3,140-share tax withholding on RSU vesting - Stock Titan
BioAtla explores sale as it cuts 70% of workforce By Investing.com - Investing.com India
BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value - Quiver Quantitative
BioAtla Inc announces 70% workforce reductionSEC filing - marketscreener.com
BioAtla appoints Chris Vasquez as CFO as Richard Waldron departs - TradingView
BioAtla (NASDAQ: BCAB) slashes workforce 70% amid strategic review, listing risk - Stock Titan
BioAtla, Inc. Implements Workforce Reduction of Approximately 70% - marketscreener.com
Bioatla announces formal process to evaluate strategic options to monetize assets - marketscreener.com
Bioatla Announces Formal Process To Evaluate Strategic Options To Monetize Assets - TradingView
Biotech BioAtla to shed 70% of staff while weighing asset sales - Stock Titan
Bioatla, Inc. Announces CFO Changes. Effective March 2, 2026 - marketscreener.com
BCAB PE Ratio & Valuation, Is BCAB Overvalued - Intellectia AI
US Market Wrap: Does BioAtla Inc meet Warren Buffetts criteria2025 Retail Activity & Low Drawdown Momentum Ideas - baoquankhu1.vn
Aug Sentiment: Is BioAtla Inc forming bullish engulfing patterns2025 Geopolitical Influence & Long-Term Safe Return Strategies - baoquankhu1.vn
BioAtla, Inc. (NASDAQ:BCAB) Sees Large Drop in Short Interest - Defense World
BioAtla (BCAB) CEO has shares withheld to cover RSU taxes - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BioAtla to Participate in the Citizens Life Sciences Conference - 富途牛牛
Gap Down: Will BioAtla Inc stock hit new highs in YEAR2025 Bull vs Bear & Accurate Intraday Trading Signals - baoquankhu1.vn
BCABBioatla, Inc. Latest Stock News & Market Updates - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aug Chart Watch: Will Nixxy Inc Equity Warrant outperform its industry peers2025 Trading Volume Trends & Accurate Buy Signal Alerts - baoquankhu1.vn
Why BioAtla Inc. stock is popular among millennials2025 Pullback Review & Entry and Exit Point Strategies - mfd.ru
What analysts say about BioAtla Inc. stockJuly 2025 Review & Growth Focused Stock Reports - mfd.ru
BCAB Should I Buy - Intellectia AI
BioAtla Sets March Virtual Vote on Internal Merger Plan - The Globe and Mail
Why BioAtla Inc. stock could see breakout soonSell Signal & Community Consensus Picks - mfd.ru
BioAtla (BCAB) seeks approval for 1‑for‑50 share conversion to support Nasdaq listing - Stock Titan
Bioatla Faces Nasdaq Delisting Review Amid Corporate Restructuring - AD HOC NEWS
Is BioAtla Inc. currently under institutional pressureQuarterly Risk Review & Technical Analysis for Trade Confirmation - mfd.ru
BioAtla Faces Nasdaq Review of Continued Listing Status - The Globe and Mail
BioAtla to remain on Nasdaq during listing council review process By Investing.com - Investing.com Canada
BioAtla to remain on Nasdaq during listing council review process - Investing.com Nigeria
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):